Gobi Partners aims to ensure high-quality healthcare through tech innovation and digital transformation
Recently, a Series A funding round for Hong Kong’s ImmunoCure was spearheaded by Gobi Partners, which also participated in the Series A funding round for Malaysia’s ORA. Spread across 12 startups within China’s Greater Bay Area (GBA) and Southeast Asia (or ‘Greater Bay ASEAN), the move strengthened the firm’s health tech portfolio with an aggregate investment of US$11.8 million (RM53.8 million).
“At Gobi Partners, we aim to ensure high-quality healthcare through tech innovation and digital transformation. Therefore, we are committed to expanding our health tech portfolio with sustainability and impact as guiding principles in our investment strategy,” said Thomas G. Tsao, Co-founder and Chairperson of Gobi Partners.
Health tech companies such as Prenetics, Biomed, Panoptic AI, ScolioScan, Gense Technologies, Immuno Cure, and ORA are included in the portfolio of Gobi Partners.
Also read: The Transformative Power of Machine Learning on OTT Platforms
Do Follow: CIO News LinkedIn Account | CIO News Facebook | CIO News Youtube | CIO News Twitter
About us:
CIO News, a proprietary of Mercadeo, produces award-winning content and resources for IT leaders across any industry through print articles and recorded video interviews on topics in the technology sector such as Digital Transformation, Artificial Intelligence (AI), Machine Learning (ML), Cloud, Robotics, Cyber-security, Data, Analytics, SOC, SASE, among other technology topics
